ERBB2 and breast cancer: Achieving pathological complete response (pCR), which is defined as the absence of invasive carcinogenic tissue in the breast and lymph nodes following NAC, strongly correlates with improved long-term survival outcomes, particularly in aggressive subtypes such as triple-negative and HER2-positive breast cancer [7].